Soleno Therapeutics, Inc. (NASDAQ:SLNO) has achieved a major regulatory milestone as the European Medicines Agency (EMA) ...

Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the ...

Obesity medications in development could improve accessibility and affordability, according to a presenter at Obesity ...

VYKAT XR was approved by the U.S. Food and Drug Administration (FDA) on March 26, 2025, and is now commercially available to ...

Option chain shows key data for Soleno Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market ...

VYKAT XR was approved by the U.S. Food and Drug Administration (FDA) on March 26, 2025, and is now commercially available to ...

Senators Shelley Moore Capito, R-W.Va., and Jeanne Shaheen, D-N.H., reintroduced the Access to Prescription Digital Therapeutics (PDT) Act on Thursday to expand access to software-based treatments.

Detailed price information for Design Therapeutics Inc (DSGN-Q) from The Globe and Mail including charting and trades.

Detailed price information for Tenaya Therapeutics Inc (TNYA-Q) from The Globe and Mail including charting and trades.

San Gabriel-based Vesicor Therapeutics, an early-stage biotech company focused on cancer therapeutics, announced plans to merge with Black Hawk Acquisition Corp., a special purpose acquisition ...

REDWOOD CITY, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare ...